Mood Disorders Overview

Principles

Definition

Mood disorders is the academic concept and research domain focused on the investigation of affective disturbances characterized by persistent or episodic alterations in mood, exploring their etiology, phenomenology, diagnosis, and treatment within the broader field of psychopathology. This research area is significant for understanding the biological, psychological, and social factors contributing to conditions like depression and bipolar disorder, and for developing effective interventions.

Ontological type

Treatment Modalities

Diagnostic Criteria

Etiology

Key developments

Key Figures

Standardized Assessment Foundation era

Aaron T. Beck [1], associated with the University of Pennsylvania [2] during this era, emerged as a central figure in standardized assessment for mood disorders. His 1961 paper, An Inventory for Measuring Depression [3], established a concrete instrument-based approach to symptom measurement, setting the stage for reliability and cross-study comparability. Beck's [1] broader program of measurement-driven research promoted psychometric rigor that linked symptom patterns to pharmacologic outcomes and treatment decisions such as electroconvulsive therapy. An Inventory for Measuring Depression [3] functioned as a template for subsequent mood-disorder instruments, anchoring standardized assessment within nosology and epidemiologic inquiry.

Neurobiological Stress Integration era

Kenneth B. Wells [1] was a scholar associated with the University of California, Los Angeles [2] and the University of California, Davis [3] during the Neurobiological Stress Integration era (1969-1997). His contributions in this era included analyses based on the Medical Outcomes Study [4], which showed that depression impairs daily functioning and quality of life, underscoring the importance of functional outcomes in mood disorder research. These efforts bridged epidemiology, neuroendocrine considerations, and clinical outcomes, reinforcing the view that stress-system dysregulation maps onto treatment response and course. By foregrounding patient-centered functioning and structured assessments, Wells helped shape biologically informed pharmacotherapy and trial design that targeted mood disorders in this period.

Transdiagnostic Genomic Precision era

Kurt Kroenke [1] is associated with the Center for Excellence in Education [3] and the University of California, San Francisco [4] during this era. His key contributions include the PHQ-9 [7] and the PHQ-4 [8], widely adopted screening tools that advanced brief, dimensional assessment of mood symptoms in primary care and research, aligning with this era's transdiagnostic approach. Robert L. Spitzer [2] is associated with the University of Washington [5] and Heidelberg University [6] in this era. His key contribution is co-developing the PHQ-9 [7], a depression diagnostic and severity measure that became a staple in clinical screening and dimensional mood assessment, supporting transdiagnostic precision care.